SWOG clinical trial number
SWOG-9221 (MDACC, ID91-025) (INT-I91-0001)

Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer

Closed
Phase
Published
Abbreviated Title
Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer
Activated
03/15/1993
Closed
04/09/1997

Research committees

Lung Cancer

Publication Information Expand/Collapse

2001

Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

SM Lippman;JJ Lee;DD Karp;EE Vokes;SE Benner;GE Goodman;FR Khuri;R Marks;RJ Winn;W Fry;SL Graziano;DR Gandara;G Okawara;CL Woodhouse;B Williams;C Perez;HW Kim;R Lotan;JA Roth;WK Hong Journal of the National Cancer Institute 93(8):605-618

1998

Phase III intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage-I non-small cell lung cancer (NSCLC): Interim report of NCI #191-0001.

SM Lippman;JJ Lee;DD Karp;EE Vokes;SE Benner;GE Goodman;C Kardinal;RJ Winn;JA Roth;WK Hong Proc of the American Society of Clinical Oncology 17:456a(#1753)

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase